

## Kortex - Corporate Venture Capital

Fleury SA ("Grupo Fleury" or "Company"), in compliance with paragraph 4 of article 157 of Law 6,404/76 and with CVM's Instruction 358 of January 3rd, 2002, as amended, informs to its shareholders and the market in general that the Company has constituted, together with Sabin Medicina Diagnóstica S.A. ("Grupo Sabin"), an equity investment fund with the objective of investing in startups that are focused on digital healthcare, diagnostic medicine and personalized medicine ("operation").

This new Corporate Venture Capital ("CVC") fund has a 10-year term and a total contribution of up to R\$ 200 million, which will be invested over the first 4 years.

The Company will hold a 70% interest and the 30% interest will be held by Grupo Sabin. Kortex Ventures ("Kortex"), one of the largest healthcare Corporate Venture Capital funds in Brazil, aims to identify market opportunities, analyzing and taking actions to generate value to the companies invested.

With this initiative, the Company will be even more connected to the ecosystem of startups and healthtechs, having the opportunity to follow the development of promising businesses and taking such innovation to its clients. The conclusion of this operation is subject to approval by CADE.

This operation is not subject to a Company's shareholders meeting, nor will it give rise to the right to withdraw.